Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Europe counts the high cost of deafness:

This article was originally published in Clinica

Executive Summary

Some E78m ($92m) is spent in Europe each year on patients with hearing impairment, European Commission figures suggest. This is higher than the combined costs of epilepsy, multiple sclerosis, spinal injury, strokes and Parkinson's disease, according to Cordis Focus, the Commission's newsletter. Over 22 million people in Europe have some kind of hearing impairment and of these some 3 million cannot hear any sound below 80-100 decibels. Some 50% of all hearing impairments have a genetic origin. There are 36 genes known to be associated with deafness. It appears that Connexin 26 is responsible for more than 30% of all deafness cases in Europe.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT063877

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel